6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile CAS 356783-31-8 Purity ≥98.0% (HPLC) Favipiravir Intermediate COVID-19

Short Description:

Chemical Name: 6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile


CAS: 356783-31-8

Appearance: Pale Yellow to Off-White Powder

Purity: ≥98.0% (HPLC)

Intermediate of Favipiravir (CAS: 259793-96-9) in the treatment of Influenza virus infections and COVID-19

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Product Detail

Related Products

Product Tags


Chemical Properties:

Chemical Name 6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile
Synonyms 6-Fluoro-3-oxo-3,4-Dihydropyrazine-2-Carbonitrile
CAS Number 356783-31-8
CAT Number RF-API294
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C5H2FN3O
Molecular Weight 139.09
Brand Ruifu Chemical


Item Specifications
Appearance Pale Yellow to Off-White Powder
Identification  IR, HPLC
Moisture (K.F) ≤1.0%
Residue on Ignition ≤0.50%
Single Impurity ≤1.0%
Total Impurities ≤2.0%
Heavy Metals  ≤20ppm
Purity ≥98.0% (by HPLC)
Test Standard Enterprise Standard
Usage Intermediate of Favipiravir (CAS 259793-96-9); Antiviral; COVID-19

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.





6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile (CAS 356783-31-8) is an Intermediate of Favipiravir (CAS 259793-96-9). Favipiravir is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp). Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia. Favipiravir can be used in the treatment of patients with COVID-19 recommended by WHO. It was cleared by the Drugs Controller General of India (DCGI) for “emergency restricted” use among COVID-19 patients. 

  • Write your message here and send it to us